Top Biotech and Pharma Stocks to Bet on Cancer Cure & Control

The technicals do not look good at all – with a decline lasting over the past two months. He would not touch this one at all. A 50 day moving average would be a buy signal if it can trade back above it.

Likes turnarounds, but it’s not ready. Want to see two things: 1) the stock hitting a 52-week high, and 2) the numbers moving in the right direction. Don’t do anything until then. Odds are this is going to zero.

Brazilian order? He owns warrants and his wife works as a consultant for them. They have orders for 500 units for a melanoma testing product. The delivery is subject to approval by authorities in Brazil. This could lead to hardware sales by June and revenues that begin to show up in Q4. The company thinks…

It has been under-performing the overall market. Biotechs don't do well at this point seasonally. Its seasonal period starts in June and the trade could setup quite well. Don't look at it at this time.

(A Top Pick Dec 03/18, Up 47%) Celgene had made a number of mis-steps, including management applying for multiple FDA approvals. One thing he really liked about the acquisition was the price it was bought. The acquisition by BMY helped them diversify and it seems to be going well.

Likes this pharma. It offers decent dividend growth and the dividend is safe. He holds pharma long term and didn't sell during Covid. Post-Covid, focus will return to non-Covid drugs, like BMY's cancer treatment.

Good quality stock that won't hurt you. Reasonable valuation, nice dividend. Bad news is everything is already built into the stock. Where's the growth past 2023? Not much upside. He'd add at $32-36, but not here at $44.

(A Top Pick Sep 30/20, Up 29%) Their primary franchise is going of patent in a couple years. They have been working on diluting its effect, especially with their purchase of Allergan. Other franchises are getting to billion dollar franchises too. The clock is ticking. FDA detemined they have to put a warning of possible…

Broadly, pharmaceuticals and healthcare space is not providing a ton of opportunity. Trading at reasonable valuations with 3 divisions. Consumer business is in trouble because more people are going towards generics. Pharma business hasn't seen much tailwind from covid vaccines.

It can't break above $90. He likes a half-dozen drug companies better.

Why bother with the U.K? The British stock market remains one of the strongest in the world and actually matched the TSX's performance in the 30 months after the pivotal June 2016 referendum (the FTSE fell off in 2019). Where to invest? Forget the British banks. They're already slumping, burdened by near-zero interest rates. Better…

Paul McDonald also recommends GSK's peer, AstraZeneca (also trading in New York and London). The pharma is focusing on its pipeline of drugs that can't be easily replicated. A third of its sales comes from the U.S., plus 20% from China, which may actually be a tailwind in this context. The New York stock (AZN-N)…

In the race to find a treatment, Gilead currently leads with its remdesivir. It's the name on every investor's lips and trading screens. Tests so far indicate that remdesivir shortens the recovery time of some Covid-19 patients, specifically those who take remdesivir recover after 11 days, which is four days faster than those who did…

It hit a new 52-week high today, based on it successful Covid treatment that gets patients out of the hospital a lot faster.

A great spec. It's a genetic engineering company so it's bought on spec, not earnings.

(A Top Pick Aug 29/14. Up 2.34%.) Radiation therapy equipment for treating cancer. Have been affected a little by foreign exchange rates. These are big ticket purchases, so she expects purchases have been delayed, but she has seen this come back. On the emerging-market side, it is a little bit more challenging. Still thinks the…

MRK vs. ABT Both are great companies. ABT is the leading supplier of glasswork to the medical industry. Merck has incredible products as a global pharmaceutical company. You could buy either one.

Trades at 34x PE, because investors believe in LLY's new Alzheimer's drug. Also, all drug stocks are rallying because of the Delta variant and calls for a booster shot.

There is renewed interest in the pharmaceutical sector after decades of being ignored. They are starting to act like value stocks. A good time to start a position in the pharma sector according to Norman Levine. Mentions have increased 22%.